Field Trip And Wesana Make Major Moves | FTRP, WESA скачать в хорошем качестве

Field Trip And Wesana Make Major Moves | FTRP, WESA

Get your 20%-off tickets to the Catalyst Psychedelics Summit in Kingston Ontario, May 20th-23rd: www.eventbrite.ca/e/153409882087/?discount=SPOTLIGHT20 Join our Newsletter (scroll to the bottom of the page and sign up): https://psychedelicspotlight.com/ Wesana Health May Sell Clinics to Focus Solely on Drug Development: An Analysis https://psychedelicspotlight.com/wesa... Why Field Trip Health Is Dividing in Two — and What This Means for Investors https://psychedelicspotlight.com/fiel... In today’s episode of the Psychedelic Investor, I discuss two major stories. First, is the news that Field Trip Health (Nasdaq: FTRP, TSX: FTRP) will be splitting into two separate companies. Next, Wesana Health (CSE: WESA, OTCQB: WSNAF) announced that they are considering selling all of their non-drug development assets, including their Psychedelic Therapy clinics. Follow us on Twitter: James: @Psy_Invest Maria: @psy_holy The Psychedelic Investor: @PSYCBiz Psychedelic Spotlight: @PsycSpotlight Follow us on Instagram: @psycbiz @psycspotlight To read more about the Field Trip situation: https://psychedelicspotlight.com/fiel... To read more about the Wesana situation: https://psychedelicspotlight.com/wesa... Field Trip Press Release: https://www.globenewswire.com/news- release/2022/04/28/2432105/0/en/Field-Trip-Health-Ltd-Announces-Intention-to-Separate-the-Field-Trip-Discovery-and-Field-Trip-Health-Divisions-Into-Two-Independent-Public-Companies.html Wesana Press Release: https://ir.wesanahealth.com/news-even... Field Trip Health: In a surprise move, Field Trip Health Ltd. announced on Thursday that they will be separating their company into two independent publicly traded entities. Assuming the ratification of shareholders and regulatory approval, come July 2022, Field Trip Health will be no more. From its ashes will rise Reunion Neuroscience Inc, and Field Trip Health and Wellness Ltd. Reunion will be the successor to Field Trip’s Discovery division, which was the part of the company which worked on next-generation psychedelics. This includes FT-104, a psilocybin-like compound that is a prodrug to 4-HO-DiPT, and the company’s FT-200 series of psychedelics, which they call third-generation. Wesana: On Thursday, Wesana Health made a major announcement. Following a planned strategic review of their assets, Wesana is considering options “including, but not limited to, a sale of all the assets under the care delivery division,” including all of their psychedelic therapy clinics. The core reasoning, according to the press release, is that Wesana wants to focus its efforts entirely on its drug development division. Prior to this announcement, Wesana was operating under a philosophy centered on “developing the novel therapies of tomorrow and delivering new care paradigms today.” If this strategic review does result in the sale of their clinics and other today-focused ventures, then Wesana will be decidedly much more focused on tomorrow. @psycspotlight #wesana #psychedelicstocks #thepsychedelicinvestor